QB3

NEW YORK (GenomeWeb News) — Mission Bio, a startup founded last year to commercialize PCR-activated cell sorting (PACS) technology developed at the University of California, San Francisco and the California Institute for Quantitative Biosciences (QB3), has been awarded a pair of National Institut

Scientists from the University of California, San Francisco, and the California Institute for Quantitative Biosciences, or QB3, have published a study demonstrating how picoinjection can be used to precisely and efficiently add reagents to individual digital PCR reaction volumes

The expansion, which will quadruple the amount of incubator space that QB3 currently operates, is designed to quench the growing thirst of life science startups for incubator space at Mission Bay.

Approximately one year after Pfizer and the California Institute for Quantitative Biosciences inked a three-year, $9.5 million drug-discovery pact, the alliance is now overseeing seven projects combining scientists from various Pfizer sites and QB3-affiliated researchers at UC-San Francisco.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.